Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Topical ophthalmic beta blockers: a comparative review

T J Zimmerman1

  • 1Department of Ophthalmology and Visual Sciences, University of Louisville School of Medicine, Kentucky Lions Eye Research Institute.

Journal of Ocular Pharmacology
|January 1, 1993
PubMed
Summary

Topical beta blockers effectively lower intraocular pressure to prevent vision loss in glaucoma patients. While generally safe, some agents like carteolol may offer better local tolerability than traditional options.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interaction between nickel and iron in the rat.

Biological trace element research·2013
Same author

Interactions among nickel, copper, and iron in rats : Growth, blood parameters, and organ wt/body wt ratios.

Biological trace element research·2013
Same author

Interactions among nickel, copper, and iron in rats : Liver and plasma content of lipids and trace elements.

Biological trace element research·2013
Same author

The glaucoma medications of the next century.

Journal of glaucoma·2009
Same author

A double-masked, placebo-controlled evaluation of timolol in a gel vehicle.

Journal of glaucoma·2009
Same author

Latanoprost and periocular skin color changes.

Archives of ophthalmology (Chicago, Ill. : 1960)·2001

Area of Science:

  • Ophthalmology
  • Pharmacology

Background:

  • Topical beta blockers are the primary medical treatment for glaucoma.
  • These medications reduce intraocular pressure (IOP), safeguarding optic nerve health and preventing vision loss.

Purpose of the Study:

  • To review the properties and side effects of available topical beta blockers for glaucoma.
  • To compare the systemic and local tolerability profiles of different beta blockers.

Main Methods:

  • Review of pharmacological properties and clinical data for topical beta blockers.
  • Analysis of systemic absorption and potential adverse effects on cardiovascular and bronchopulmonary systems.
  • Evaluation of local adverse effects, including stinging, burning, and corneal sensitivity.

Main Results:

  • Available topical beta blockers (timolol, betaxolol, levobunul, metipranolol, carteolol) demonstrate similar IOP-lowering efficacy.
  • Systemic absorption can lead to adverse effects in patients with pre-existing conditions.
  • Betaxolol (beta 1-selective) and carteolol (with ISA) may offer improved systemic tolerability.
  • Carteolol shows preliminary evidence of superior local tolerability, while betaxolol is associated with frequent stinging.

Conclusions:

  • Topical beta blockers are essential for glaucoma management, but systemic absorption necessitates caution in susceptible patients.
  • Further clinical trials are needed to confirm the superior systemic tolerability of betaxolol and carteolol.
  • Carteolol may be a preferred option due to its favorable local tolerability profile.

Related Experiment Videos